Context Therapeutics (CNTX) Expected to Post Earnings on Wednesday

Context Therapeutics (NASDAQ:CNTX) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. On average, analysts expect Context Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $0.59 on Wednesday. The company has a market cap of $54.26 million, a price-to-earnings ratio of -1.41 and a beta of 1.75. The stock’s fifty day moving average price is $1.19 and its 200 day moving average price is $1.97. Context Therapeutics has a 1 year low of $0.55 and a 1 year high of $3.62.

Hedge Funds Weigh In On Context Therapeutics

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after buying an additional 134,449 shares during the period. Millennium Management LLC purchased a new position in shares of Context Therapeutics in the 4th quarter valued at about $3,824,000. Marshall Wace LLP boosted its position in Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after purchasing an additional 2,557,448 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares during the period. Finally, State Street Corp grew its holdings in Context Therapeutics by 8.5% in the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after purchasing an additional 13,000 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CNTX has been the topic of several research analyst reports. Wall Street Zen downgraded Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Friday, July 17th. Finally, Maxim Group reduced their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $6.17.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.